AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)Heinz Gisslinger, Josef Thaler, Veronika Buxhofer‐Ausch et al.|Blood|2012Cited by 5
Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing StudyHeinz Gisslinger, Josef Thaler, Róbert Královics et al.|Blood|2011Cited by 2